10-bromodecanoyl chloride | 73674-11-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: 10-bromodecanoyl chloride
• CAS: 73674-11-0
• 化学式: C₁₀H₁₈BrClO
• 分子量: 269.609
• InChiKey: YZLCFQNDDOKXQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  13
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  10-bromodecanoyl chloride 在 ammonium hydroxide 、 三氟甲磺酸酐 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 2.5h， 生成 10-bromodecanenitrile
  参考文献：
  名称：

  选择性高尔基体 α-甘露糖苷酶 II 抑制剂：具有碱性官能团的 N-烷基取代的吡咯烷

  摘要：

  N-烷基化 1,4-二脱氧-1,4-亚氨基-L - lyxitol（N-烷基化聚羟基吡咯烷）的烷基链长度（从 C7 到 C14）和它们的封端官能团（甲基、胺、脒和胍）不同已经合成。基于分子模型，这些结构被设计为高尔基体 α-甘露糖苷酶 II (GMIIb) 的选择性抑制剂，预计对溶酶体 α-甘露糖苷酶 II (LManII) 的结合亲和力降低。通常，衍生物对 GMIIb 的效力按以下顺序降低：脒> 胍 > 烷烃 > 胺。GMIIb 最有效的抑制剂是N-壬脒和N-癸脒 1,4-dideoxy-1,4- imino - L - lyxitols [ K i(GMIIb) = 4.0 μM 和 5.5 μM]。烷基链的延长导致效力增加，同时保持对目标酶的选择性。分子对接表明，在脒、胍和胺结构的情况下，烷基链长度对于末端基团与极性二元组（Asp270-Asp340）以及疏水袋（Pro298-Trp

  DOI：

  10.1039/d1nj01176f
• 作为产物：
  描述：

  10-溴-1-癸醇 在 氯化亚砜 、 硝酸 作用下， 生成 10-bromodecanoyl chloride
  参考文献：
  名称：

  Syntheses and Physical Properties of Ferrocene Derivatives (XIII)

  摘要：

  Two monosubstituted ferrocene derivatives, 8-[4-(4-methoxyphenoxycarbonyl)phenoxycarbonyl]octyl 4-ferrocenylbenzoate (MPAF-8) and 9-[4-(4-methoxyphenoxycarbonyl)phenoxycarbonyl] nonyl 4-ferrocenylbenzoate (MPAF-9), were synthesized and their phase transition behavior was studied using a differential scanning calorimeter. a polarizing microscope and an X-ray diffractometer. MPAF-8 exhibited two liquid crystalline phases in both heating and cooling processes at approximately room temperature. In the heating process. a crystal-crystal phase transition behavior was ascertained. The phase transition behavior of MPAF-9 was very similar to that of MPAF-8 except for the behavior of the crystal-crystal phase transition in the heating process. In MPAF-B. one crystalline phase was transformed into another crystalline phase completely. On the other hand, this transformation was observed in part in MPAF-9, and as a result, the melting behavior was observed two times in the heating process.

  DOI：

  10.1080/10587250008025236

文献信息

• Design of Nanosystems for the Delivery of Quorum Sensing Inhibitors: A Preliminary Study
  作者：Supandeep Singh Hallan、Paolo Marchetti、Daria Bortolotti、Maddalena Sguizzato、Elisabetta Esposito、Paolo Mariani、Claudio Trapella、Roberta Rizzo、Rita Cortesi

  DOI：10.3390/molecules25235655

  日期：——

  Biofilm production is regulated by the Quorum Sensing system. Nowadays, Quorum Sensing represents an appealing target to design new compounds to increase antibiotics effects and avoid development of antibiotics multiresistance. In this research the use of liposomes to target two novel synthetic biofilm inhibitors is presented, focusing on a preformulation study to select a liposome composition for in vitro test. Five different liposome (LP) formulations, composed of phosphatidyl choline, cholesterol and charged surfactant (2:1:1, molar ratio) have been prepared by direct hydration and extrusion. As charged surfactants dicetyl phosphate didecyldimethylammonium chloride, di isobutyl phenoxy ethyl dimethyl benzyl ammonium chloride and stearylamine (SA) and have been used. Liposome charge, size and morphology were investigated by zeta potential, photon correlation spectroscopy, small angle x-ray spectroscopy and electron microscopy. LP-SA was selected for the loading of biofilm inhibitors and subjected to high performance liquid chromatography for entrapment capacity evaluation. LP-SA loaded inhibitors showed a higher diameter (223.6 nm) as compared to unloaded ones (205.7 nm) and a dose-dependent anti-biofilm effect mainly after 48 h of treatment, while free biofilm inhibitors loose activity. In conclusion, our data supported the use of liposomes as a strategy to enhance biofilm inhibitors effect.

  生物膜的生成受到群体感应系统的调控。如今，群体感应代表着一个吸引人的目标，用于设计新化合物以增强抗生素的效果并避免抗生素多重耐药性的发展。本研究介绍了利用脂质体来靶向两种新型合成生物膜抑制剂的方法，重点是进行预配方研究以选择适合体外测试的脂质体组成。通过直接水合和挤压法制备了五种不同的脂质体（LP）配方，由磷脂酰胆碱、胆固醇和带电表面活性剂（摩尔比2:1:1）组成。使用了带电表面活性剂二十二烷基磷酸二十二烷基二甲基氯化铵、二异丁基苯氧乙基二甲基苄基氯化铵和硬脂胺（SA）。通过ζ电位、光子相关光谱、小角度X射线光谱和电子显微镜研究了脂质体的电荷、大小和形态。选择了LP-SA用于载荷生物膜抑制剂，并进行了高效液相色谱法评估其包封能力。LP-SA载荷的抑制剂显示出较大的直径（223.6纳米），与未载荷的抑制剂（205.7纳米）相比，并且在治疗48小时后主要呈剂量依赖的抗生物膜效果，而游离的生物膜抑制剂失去活性。总之，我们的数据支持使用脂质体作为增强生物膜抑制剂效果的策略。
• A Twist-Bend Nematic (N_TB) Phase of Chiral Materials
  作者：Ewa Gorecka、Nataša Vaupotič、Anna Zep、Damian Pociecha、Jun Yoshioka、Jun Yamamoto、Hideo Takezoe

  DOI：10.1002/anie.201502440

  日期：2015.8.24

  New chiral dimers consisting of a rod‐like and cholesterol mesogenic units are reported to form a chiral twist‐bend nematic phase (NTB*) with heliconical structure. The compressibility of the NTB phase made of bent dimers was found to be as large as in smectic phases, which is consistent with the nanoperiodic structure of the NTB phase. The atomic force microscopy observations in chiral bent dimers

  据报道，由棒状和胆固醇介晶单元组成的新手性二聚体形成具有螺旋结构的手性扭曲弯曲向列相（N TB *）。发现由弯曲二聚体制成的N TB相的可压缩性与近晶相一样大，这与N TB相的纳米周期结构是一致的。在手性弯曲的二聚体上进行的原子力显微镜观察发现，其周期性约为50 nm，这大大大于先前报道的非手性化合物的周期性（约10 nm）。
• [EN] RETINAL BIOAVAILABILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS<br/>[FR] BIODISPONIBILITÉ RÉTINIENNE D'ACIDES GRAS POLYINSATURÉS À TRÈS LONGUE CHAÎNE SYNTHÉTIQUES
  申请人：UNIV UTAH RES FOUND

  公开号：WO2021257636A1

  公开（公告）日：2021-12-23

  The rare non-dietary very-long-chain polyunsaturated fatty acids (VLC-PUFAs) uniquely found in retina and a few other tissues play a clinically significant role in retinal degeneration and development, but their physiological and interventional research has been hampered by scarcity of pure VLC-PUFAs. Disclosed herein are methods of making fatty acids, including VLC-PUFAs, and methods of using these fatty acids in, for example, treating eye disorders and supplementing the diet of a female subject who is pregnant, desiring to become pregnant, or lactating. Also disclosed are compositions containing fatty acids and methods of making and using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  罕见的非膳食非常长链多不饱和脂肪酸（VLC-PUFAs）独特地存在于视网膜和少数其他组织中，在视网膜退化和发育中发挥着临床重要作用，但由于纯度不足的限制，它们的生理和干预研究受到了阻碍。本文披露了制备脂肪酸（包括VLC-PUFAs）的方法，以及利用这些脂肪酸治疗眼部疾病和补充怀孕、希望怀孕或哺乳的女性受试者饮食的方法。还披露了含有脂肪酸的组合物以及制备和使用这些组合物的方法。本摘要旨在作为在特定领域搜索的扫描工具，并不打算限制本发明。
• The synthesis of the very long chain polyunsaturated fatty acid (VLC-PUFA) 32:6 n-3
  作者：Alexander Wade、Rameshu Rallabandi、Steven Lucas、Catrina Oberg、Aruna Gorusupudi、Paul S. Bernstein、Jon D. Rainier

  DOI：10.1039/d1ob00491c

  日期：——

  This article describes the synthesis of VLC-PUFA 32:6 n-3, D2-labeled 32:6 n-3, and the uptake of 32:6 n-3 into mouse retinal tissue.

  本文介绍了 VLC-PUFA 32:6 n-3、D 2标记的 32:6 n-3 的合成，以及 32:6 n-3 进入小鼠视网膜组织的过程。
• Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization
  作者：Agnès Quéméner、Mike Maillasson、Laurence Arzel、Benoit Sicard、Romy Vomiandry、Erwan Mortier、Didier Dubreuil、Yannick Jacques、Jacques Lebreton、Monique Mathé-Allainmat

  DOI：10.1021/acs.jmedchem.7b00485

  日期：2017.7.27

  approaches targeting IL-15. This study is an original approach aimed at discovering small-molecule inhibitors impeding IL-15/IL-15R interaction. A pharmacophore and docking-based virtual screening of compound libraries led to the selection of 240 high-scoring compounds, 36 of which were found to bind IL-15, to inhibit the binding of IL-15 to the IL-2Rβ chain or the proliferation of IL-15-dependent cells or

  白介素（IL）-15是一种多效细胞因子，在结构上接近IL-2，并与之共享IL-2β和γ受体（R）亚基。通过促进NK，NK-T和CD8 + T细胞的活化和增殖，IL-15在先天和适应性免疫中起着重要的作用。而且，高水平的IL-15表达与炎性和自身免疫性疾病的关联导致了针对IL-15的各种拮抗方法的发展。这项研究是旨在发现阻碍IL-15 / IL-15R相互作用的小分子抑制剂的原始方法。对化合物库进行药效学和基于对接的虚拟筛选导致选择了240种高得分化合物，其中36种被发现与IL-15结合，从而抑制IL-15与IL-2Rβ链的结合或增殖IL-15依赖性细胞或两者兼有。